For most stocks, a 25% cut in an analyst’s target price following an earnings release would send investors scrambling for the exit door. That wasn’t the case with Bluebird Bio (NASDAQ: BLUE), however. The clinical-stage biotech saw a decent price rise after those two events in late March. What helped was that, despite the cut, […]
Businessman checking his phone. It has been just over two years since Bluebird Bio (NASDAQ: BLUE) split into two separate companies. One focused on gene therapies and retained the Bluebird name; another focused on oncology, and now goes under the name 2seventy Bio. Below, I’ll look at what your returns would look like if you […]
Patient sitting on hospital bed. No stock is entirely risk-free, especially stocks like Bluebird Bio (NASDAQ: BLUE). The small-cap company’s shares have plunged by 84% in the past three years. The gene editing specialist has had clinical, regulatory, and financial issues that account for its lagging the market. However, some might think that at current […]